Theriva Biologics (TOVX) Receivables - Other (2012 - 2026)
Theriva Biologics (TOVX) posted quarterly Receivables - Other of $14000.0 for Q1 2026, down 87.16% year-over-year from $109000.0 in Q1 2025, and down 86.41% quarter-over-quarter from $103000.0 in Q3 2025.
Theriva Biologics (TOVX) Receivables - Other (2012 - 2026) Analysis & Trends
Theriva Biologics (TOVX) has reported Receivables - Other for 11 consecutive years, with $14000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables - Other fell 87.16% year-over-year to $14000.0; the TTM figure through Mar 2026 stood at $14000.0 (down 87.16% YoY), while the FY2024 annual figure was $95000.0, down 25.78% from the prior year.
- Receivables - Other eased to $14000.0 in Q1 2026 per TOVX's latest filing, from $103000.0 in the prior quarter.
- Across five years, Receivables - Other topped out at $278000.0 in Q2 2022 and bottomed at $4000.0 in Q1 2023.
- Historically, Receivables - Other has averaged $130812.5 across 5 years, with a median of $132000.0 in 2023.
- Annual changes were most pronounced in 2023 — Receivables - Other sank 96.85% — and 2024, when it surged 3300.0%.
- Theriva Biologics' Receivables - Other stood at $176000.0 in 2022, then decreased by 27.27% to $128000.0 in 2023, then retreated by 25.78% to $95000.0 in 2024, then grew by 8.42% to $103000.0 in 2025, then slumped by 86.41% to $14000.0 in 2026.
- Business Quant data shows TOVX's Receivables - Other at $14000.0 in Q1 2026, $103000.0 in Q3 2025, and $48000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Theriva Biologics | 10.64 Mn | 10.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21,000.00 |
| Jun 30, 2026 | 21,000.00 |
| Mar 31, 2026 | 14,000.00 |
| Mar 31, 2026 | 14,000.00 |
| Sep 30, 2025 | 103,000.00 |
| Sep 30, 2025 | 103,000.00 |
| Jun 30, 2025 | 48,000.00 |
| Jun 30, 2025 | 48,000.00 |
| Mar 31, 2025 | 109,000.00 |
| Mar 31, 2025 | 109,000.00 |
| Dec 31, 2024 | 95,000.00 |
| Dec 31, 2024 | 95,000.00 |
| Sep 30, 2024 | 170,000.00 |
| Sep 30, 2024 | 170,000.00 |
| Jun 30, 2024 | 171,000.00 |
| Jun 30, 2024 | 171,000.00 |
| Mar 31, 2024 | 136,000.00 |
| Mar 31, 2024 | 136,000.00 |
| Dec 31, 2023 | 128,000.00 |
| Dec 31, 2023 | 128,000.00 |